Status:
COMPLETED
Evaluation of the Efficacy, Safety and Toleration of CT327 Ointment in Patients With Psoriasis Vulgaris
Lead Sponsor:
Creabilis SA
Conditions:
Psoriasis Vulgaris
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to evaluate the effectiveness of 3 dose strengths of CT327 ointment (0.05%, 0.1% and 0.05% w/w) compared to a placebo, when applied twice daily for up to 8 weeks, to the p...
Eligibility Criteria
Inclusion
- Male and female subjects aged at least 18 years.
- Stable psoriasis vulgaris
Exclusion
- Subjects with guttate, erythrodermic, exfoliative or pustular psoriasis.
Key Trial Info
Start Date :
December 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2012
Estimated Enrollment :
160 Patients enrolled
Trial Details
Trial ID
NCT01465282
Start Date
December 1 2011
End Date
September 1 2012
Last Update
March 8 2013
Active Locations (13)
Enter a location and click search to find clinical trials sorted by distance.
1
Hotsprings, Arkansas, United States
2
San Ramon, California, United States
3
Bay City, Michigan, United States
4
Fridley, Minnesota, United States